Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome

Detalhes bibliográficos
Autor(a) principal: Henriques, Luciana dos Santos
Data de Publicação: 2012
Outros Autores: Matos, Fabíola de Marcos, Vaisbich, Maria Helena
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/47933
Resumo: OBJECTIVE: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state. METHOD: The pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the timeconcentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the timeconcentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the timeconcentration curve. ClinicalTrials.gov:NCT01616446. RESULTS: There were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states. CONCLUSIONS: These data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.
id USP-19_4d2976d45cd4eb5e6af58ca58cd3ad70
oai_identifier_str oai:revistas.usp.br:article/47933
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndromeCyclosporin-ANephrotic SyndromeChildrenPharmacokineticsArea Under CurveOBJECTIVE: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state. METHOD: The pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the timeconcentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the timeconcentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the timeconcentration curve. ClinicalTrials.gov:NCT01616446. RESULTS: There were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states. CONCLUSIONS: These data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2012-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/4793310.6061/clinics/2012(10)12Clinics; Vol. 67 No. 10 (2012); 1197-1202Clinics; v. 67 n. 10 (2012); 1197-1202Clinics; Vol. 67 Núm. 10 (2012); 1197-12021980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/47933/51673Henriques, Luciana dos SantosMatos, Fabíola de MarcosVaisbich, Maria Helenainfo:eu-repo/semantics/openAccess2012-12-13T11:01:04Zoai:revistas.usp.br:article/47933Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-12-13T11:01:04Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
title Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
spellingShingle Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
Henriques, Luciana dos Santos
Cyclosporin-A
Nephrotic Syndrome
Children
Pharmacokinetics
Area Under Curve
title_short Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
title_full Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
title_fullStr Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
title_full_unstemmed Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
title_sort Pharmacokinetics of cyclosporin: a microemulsion in children with idiopathic nephrotic syndrome
author Henriques, Luciana dos Santos
author_facet Henriques, Luciana dos Santos
Matos, Fabíola de Marcos
Vaisbich, Maria Helena
author_role author
author2 Matos, Fabíola de Marcos
Vaisbich, Maria Helena
author2_role author
author
dc.contributor.author.fl_str_mv Henriques, Luciana dos Santos
Matos, Fabíola de Marcos
Vaisbich, Maria Helena
dc.subject.por.fl_str_mv Cyclosporin-A
Nephrotic Syndrome
Children
Pharmacokinetics
Area Under Curve
topic Cyclosporin-A
Nephrotic Syndrome
Children
Pharmacokinetics
Area Under Curve
description OBJECTIVE: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state. METHOD: The pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the timeconcentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the timeconcentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the timeconcentration curve. ClinicalTrials.gov:NCT01616446. RESULTS: There were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states. CONCLUSIONS: These data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.
publishDate 2012
dc.date.none.fl_str_mv 2012-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/47933
10.6061/clinics/2012(10)12
url https://www.revistas.usp.br/clinics/article/view/47933
identifier_str_mv 10.6061/clinics/2012(10)12
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/47933/51673
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 67 No. 10 (2012); 1197-1202
Clinics; v. 67 n. 10 (2012); 1197-1202
Clinics; Vol. 67 Núm. 10 (2012); 1197-1202
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222759172702208